CytoMed Therapeutics Announces Board Re-organization

Ticker: GDTC · Form: 6-K · Filed: Jun 20, 2024 · CIK: 1873093

Cytomed Therapeutics LTD 6-K Filing Summary
FieldDetail
CompanyCytomed Therapeutics LTD (GDTC)
Form Type6-K
Filed DateJun 20, 2024
Risk Levellow
Pages1
Reading Time1 min
Sentimentneutral

Sentiment: neutral

Topics: governance, board-of-directors, regulatory-filing

TL;DR

CytoMed Therapeutics is shuffling its board as per its constitution.

AI Summary

CytoMed Therapeutics Ltd. filed a Form 6-K on June 20, 2024, reporting a board re-organization. This action is in accordance with Regulation 117 of the Company's Constitution, which mandates the rotation of one-third of the Board of Directors.

Why It Matters

Board re-organizations can signal changes in company strategy or governance, potentially impacting investor confidence and future operational direction.

Risk Assessment

Risk Level: low — The filing is a routine procedural update regarding board composition and does not indicate significant financial or operational changes.

Key Players & Entities

FAQ

What is the specific reason for the board re-organization at CytoMed Therapeutics Ltd.?

The board re-organization is a mandatory action required by Regulation 117 of the Company's Constitution, which stipulates the rotation of one-third of the Board of Directors.

When was this Form 6-K filed with the SEC?

This Form 6-K was filed on June 20, 2024.

Does this filing indicate any changes to CytoMed Therapeutics' financial status?

No, this filing specifically pertains to a board re-organization and does not contain information about the company's financial status.

What is the principal executive office address for CytoMed Therapeutics?

The principal executive office is located at 1 Commonwealth Lane #08-22, Singapore 149544.

Is CytoMed Therapeutics required to file annual reports on Form 20-F or 40-F?

Yes, CytoMed Therapeutics is indicated to file annual reports under cover of Form 20-F.

Filing Stats: 362 words · 1 min read · ~1 pages · Grade level 12.2 · Accepted 2024-06-20 13:50:27

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. CytoMed Therapeutics Limited Date: June 20, 2024 By: /s/ CHOO Chee Kong CHOO Chee Kong Director and Chairman

View Full Filing

View this 6-K filing on SEC EDGAR

View on Read The Filing